scispace - formally typeset
L

Luke R. Odell

Researcher at Uppsala University

Publications -  126
Citations -  2521

Luke R. Odell is an academic researcher from Uppsala University. The author has contributed to research in topics: Aryl & Catalysis. The author has an hindex of 27, co-authored 116 publications receiving 2150 citations. Previous affiliations of Luke R. Odell include University of Newcastle & Children's Medical Research Institute.

Papers
More filters
Journal ArticleDOI

Molybdenum Hexacarbonyl Mediated CO Gas-Free Carbonylative Reactions

TL;DR: In this paper, the authors summarize their own experiences in developing microwave-heated palladium-catalyzed Mo(CO)6-mediated gas-free carbonylative reactions.
Journal ArticleDOI

Inhibition of dynamin mediated endocytosis by the dynoles--synthesis and functional activity of a family of indoles.

TL;DR: The dynoles represent a new series of tools to better probe endocytosis and dynamin-mediated trafficking events in a variety of cells and are the most active dynamin I inhibitors reported for in vitro or RME evaluations.
Journal ArticleDOI

Comprehensive mapping of neurotransmitter networks by MALDI-MS imaging.

TL;DR: F fluoromethylpyridinium-based reactive matrices facilitate the covalent charge-tagging of molecules containing phenolic hydroxyl and/or primary or secondary amine groups, including dopaminergic and serotonergic neurotransmitters and their associated metabolites.
Journal ArticleDOI

Aminocarbonylations employing Mo(CO)6 and a bridged two-vial system: allowing the use of nitro group substituted aryl iodides and aryl bromides.

TL;DR: A bridged two-vial system aminocarbonylation protocol where Mo(CO)(6) functions as an external in situ solid source of CO has been developed and for the first time both nitro group containing aryl/heteroaryl iodides and bromides gave good to excellent yields.
Journal ArticleDOI

Functionalized 3-amino-imidazo[1,2-a]pyridines : A novel class of drug-like Mycobacterium tuberculosis glutamine synthetase inhibitors

TL;DR: 3-Amino-imidazo[1,2-a]pyridines have been identified as a novel class of Mycobacterium tuberculosis glutamine synthetase inhibitors and a series of compounds exploring structural diversity in the pyridine and phenyl rings have been synthesized and biologically evaluated.